Aastrom Biosciences, Inc. (NASDAQ:ASTM)

NuclearSteve (< 20) Submitted: 12/29/2011 12:49:57 PM : Start Price: $1.82 ASTM Score: -6.25

Article from Zacks Biotech Guy - Jason Napodano - trying a strategy where I set 10% stops on all these and let the winners run.

flrs81 (< 20) Submitted: 5/2/2011 10:37:29 PM : Start Price: $2.82 ASTM Score: -33.93

waiting for the phase 3 results, go ASTM

alphadogg (91.69) Submitted: 3/14/2011 7:56:29 AM : Start Price: $2.24 ASTM Score: -21.67

strong insider buying

sugarsugar123 (< 20) Submitted: 3/8/2011 12:05:51 PM : Start Price: $2.36 ASTM Score: -23.55

improves peoples lives with stem cells introduced into hearts making people regain their lives the heart increases its blood flow and people can walk and exercise again those peoplewho had very little chance even with heart surgery

ztur2218 (< 20) Submitted: 3/6/2011 8:58:47 AM : Start Price: $2.35 ASTM Score: -23.26

risk

captsteve66 (< 20) Submitted: 1/12/2011 9:48:25 AM : Start Price: $3.04 ASTM Score: -44.69

rated buy. cell structure is the future?

pick1998 (86.37) Submitted: 11/15/2010 5:04:23 PM : Start Price: $3.55 ASTM Score: -61.08

While I am almost 100% skeptical of Garza's pump on biomedreports.com, I do find that ASTM will have a very good chance to demonstrate historical stem cell therapy first in CLI.

The interim data (n=46) was significant. But the number of patients was small, treatment time was only 6 months.

We will see the whole data set (n=86) on Nov 18. This is a phase IIb, randomized, placebo-controlled, and double-blinded trial. Half of patients will have a treatment of 12 months. We don't have to wait too long to see the data.

If the data is significant, ASTM will triple its price. There are numerous cases in biotech that may be called "black swans".

As the recent CLI trial by Sanofi/Vical has failed, the significance of ASTM stem cell therapy will be enormous should the data be good.

Let's wait and see.

ICanFool (< 20) Submitted: 11/15/2010 4:48:20 PM : Start Price: $3.55 ASTM Score: -61.08

DCM patient(see on the webpages of ASTM) is alive and well. Motley Fools report does not recognize that. And that is Insane. Who is paying you to discredit ASTM. You guys must be out of your mind, just like Cramer!!
Read the report by Scimitar and Zacks...

platinumplay (< 20) Submitted: 7/9/2010 3:03:39 AM : Start Price: $1.57 ASTM Score: -8.86

Going to phase 3 and promising result at phase 2B. Ischemia therapy - anything that improves patient condition at this stage is an improvement over amputation.

rtrieone (< 20) Submitted: 4/9/2007 9:08:39 PM : Start Price: $12.24 ASTM Score: -83.46

They will need time to get the studies done. This stuff works and very exciting to see it all come alive and make a lot of money investing....

scott627 (< 20) Submitted: 4/8/2007 7:10:02 PM : Start Price: $12.88 ASTM Score: -84.00

Using audlt stem cells may take the edge off the whole stem cell debate. They will need to push hard the "adult" angle to come out a winner.

wynharter (< 20) Submitted: 2/23/2007 1:35:31 PM : Start Price: $12.00 ASTM Score: -82.94

Their TRC's are non-invasive, personal blood stem cells, being proven a success in clinics and create no side affects. Also non-controversal and morally acceptable.

wyn harter

verncox (< 20) Submitted: 2/14/2007 11:46:06 PM : Start Price: $12.16 ASTM Score: -82.85

Flucuates between .50 and 5.00